Semaglutide biosimilar(Huisheng Biopharm)

司美格鲁肽生物类似药（惠升生物）

Report date: 2026/04/01 10:52:25

Base Information

Drug NameSemaglutide biosimilar(Huisheng Biopharm)
Drug Alias Namesemaglutida索马鲁肽semaglutidum索玛鲁肽司美鲁肽 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesJilin Huisheng Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJilin Huisheng Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG